Scientists to study role-switching cells in heart failure

July 16, 2012

The National Institutes of Health has awarded more than $2 million to a team of scientists from Washington University in St. Louis and InvivoSciences, a biotechnology startup with WUSTL roots, to construct artificial tissue models that will allow the rapid testing of new drugs for heart failure.

According to the Centers for Disease Control, about 5.8 million people in the United States have , and many of them will die of their disease.

Drugs used to treat failure, such as the or beta blockers, improve the symptoms and allow patients to live longer and feel better. They may even reverse in the heart tissue to some degree.

But heart failure is still the leading diagnosis and trials for several for this disease have been spectacular and costly failures.

The WUSTL research focuses on the role in heart disease of role-switching cells called that proliferate in over-stressed or injured hearts. In response to a heart attack, fibroblasts convert to this cell type, which secretes collagen and contracts the matrix of fibers around the injured heart tissue to repair the defect.

The video will load shortly.
Here an electrical impulse propagating erratically through a highly fibrotic artificial tissue is made visible with a voltage-sensitive dye. The image was taken on an Elson lab tissue construct by members of the Efimov lab. Credit: Elson/Efimov

But never truly regenerate in the damaged tissue, and myofibroblasts compensate for their absence by forming a stiff, collagenous scar that interferes with the heart's ability to maintain stable and to expand and contract forcefully to pump blood.

Fibroblasts also convert to myofibroblasts in response to , or hypertension. The resulting diffuse invasion of myofibroblasts also interferes with the electrical and mechanical functions of the tissue, and can lead to heart failure.

"Drugs that block the effects of myofibroblasts on the electrical or mechanical properties of heart tissue or that coax them to revert to fibroblasts might be more effective than current therapies," says Guy M. Genin, PhD, associate professor of mechanical engineering and materials science in WUSTL's School of Engineering & Applied Science, who is one of three co-primary investigators (PI) on the grant.

A wound-healer run amok

In the 1970s, a scientist at the University of Geneva in Switzerland discovered cells in healing wounds that seemed to be intermediate in character between fibroblasts, which secrete fibers such as collagen that make up the matrix that holds cells together in tissues, and smooth muscle cells, like those in the intestines and blood vessels.

These cells, which were named myofibroblasts to reflect their double nature, secrete fibers to fill in a wound and then contract to bring together its edges. And after the wound is healed, they disappear, either by committing cell suicide or perhaps by reverting to their original cell type.

But not always.

The heart is made up predominantly of two types of cells, Genin says: the fibroblasts, which maintain the collagen and other structural proteins within the heart, and the cardiomyocytes, which do the pumping.

The video will load shortly.
In this movie of an artificial tissue, the heart muscle cells are beating in an abnormal rhythm called cardiac alternans, where a full beat alternates with a partial beat. The heart rhythm is made visible by an indicator molecule that fluoresces when calcium ions flood into the cell at the beginning of an action impulse. Credit: The movie was created by Teresa M. Abney, Ph.D., as part of her doctoral work in the Genin and Elson labs.

After a heart attack, some of the fibroblasts will convert to myofibroblasts to restore tissue integrity, and many persist even after their work is done. If blood pressure is high enough to provoke fibroblasts to become myofibroblasts, the cells also may get stuck in their helper state.

The cardiomyocytes don't proliferate, but the myofibroblasts keep dividing, gradually replacing healthy tissue with fiber-stiffened (fibrotic) tissue.

This phenomenon is not limited to the heart. Myofibroblasts can proliferate elsewhere in the body as well — although they may arise from different cell types in different tissues — and fibrotic remodeling of the kidney, liver (cirrhosis of the liver) and lungs follows a similar progression, Genin says.

The severe consequences of myofibroblast dysfunction motivate the effort to better understand these enigmatic cells.

Artificial heart tissue

"There's a lot we don't understand about what these cells do in the heart," Genin says.

"We don't know why conversion of fibroblasts to the contractile phenotype is sometimes helpful and sometimes harmful. We don't know how these cells alter the electrical and mechanical properties of heart tissue, or the degree to which these changes are to blame for the ultimate shutdown of the heart.

"We think that a therapy that would control the number and properties of myofibroblasts in the heart might be useful, but we don't know that for sure," Genin adds. "Nor do we know how to reverse the transition to this cell phenotype once it has occurred."

The video will load shortly.
The scientists are also developing computer models of heart tissue are multicellular versions of a mathematical model of a cardiac cell developed by WUSTL scientist Yorum Rudy. Shown here is a model of interstitial fibrosis characteristic of sustained high blood pressure. The fibrotic areas break up a calcium wave as it hits them, a clue to why high blood pressure can lead to fatal arrhythmias. Credit: Teresa M. Abney, Ph.D., as part of her doctoral work in the Genin and Elson labs.

Many of these questions would be very difficult to sort out in real tissue, so the scientists use model tissues invented at WUSTL in Eliot Elson's lab. Elson, PhD, the Alumni Endowed Professor of Biochemistry and Molecular Biophysics in the Department of Biochemistry and Molecular Biophysics at WUSTL's School of Medicine, is the second of three co-PIs on the grant.

To make the tissues, the scientists crack open fertilized chicken eggs, pull fibroblasts and muscle cells out of the embryos' hearts, and mix them together with collagen.

"Over the course of time, the cells interact with each other and the collagen to form pieces of artificial heart that beat on their own in a Petri dish," Elson says.

The scientists can control the number of myofibroblasts in the tissue (most fibroblasts convert to myofibroblasts when they are plated out) and their distribution. In this way, they can mimic the fibrotic changes characteristic of a heart attack and those characteristic of hypertension.

"For a model of myocardial infarction, we want to create an island of wound-healing cells inside a patch of heart tissue, and for hypertension, we try to create what's called interstitial fibrosis, in which the myofibroblasts are interspersed between the contractile cells," Genin says.

The electrical and mechanical activity of the manufactured tissues then can be investigated with the help of a variety of sophisticated imaging and force measurement techniques, many developed at WUSTL in the laboratories of Elson and Genin, and of Igor Efimov, PhD, the Lucy and Stanley Lopata Distinguished Professor of Biomedical Engineering in the School of Engineering & Applied Science.

At the same time, the scientists are developing computer models that are digital analogs of the artificial tissues, including electrophysiological models pioneered by Yoram Rudy, PhD, the Fred Saigh Distinguished Professor of Engineering in the School of Engineering & Applied Science. The back and forth between the tissue models and the computer models will allow them to test basic biophysical theories explaining their experimental observations.

Drug screening with tissue constructs

Once they understand the basic cellular biophysics of failing , they will transfer their work to tissue models that will make it much faster and safer to test drugs for heart failure and hypertensive heart disease, the scientists say.

They plan to make the transition to drug screening with the help of InvivoSciences, whose chief scientist Tetsuro Wakatsuki, PhD, the third PI on the grant, earned a doctorate in biophysics and a master's degree in mechanical engineering at Washington University.

InvivoSciences makes engineered heart tissues from mouse embryonic stem cells and stem cells from differentiated adult tissues in humans, such as fat and skin. The company then uses biochemical methods to convert these undifferentiated cells to tissue- or organ-specific , such as cardiomyocytes and fibroblasts, and to generate artificial tissues from them.

"We'll develop the science on the much less expensive chicken egg tissues and then we'll start our own stem cell bank here and begin making these mouse-derived constructs," Elson says. The mouse constructs are more useful because of the molecular genetic tools available for mice.

Staggering investments of time and money have failed to produce for heart failure. The scientists hope that the artificial tissues will allow many more drugs to be tested under conditions closer to those within the human body. Their hope is that drug candidates that get as far as animal testing and clinical trials will then be more likely to be safe and effective.

Explore further: Bear bile chemical could help keep hearts in rhythm

Related Stories

Bear bile chemical could help keep hearts in rhythm

August 2, 2011
A synthesised compound which is also found in bear bile could help prevent disturbances in the heart's normal rhythm, according to research published today in the journal Hepatology by a team from Imperial College London.

Scar tissue turned into heart muscle without using stem cells

April 26, 2012
Scientists at Duke University Medical Center have shown the ability to turn scar tissue that forms after a heart attack into heart muscle cells using a new process that eliminates the need for stem cell transplant.

Genetically engineered cardiac stem cells repaired damaged mouse heart

July 19, 2011
Genetically engineered human cardiac stem cells helped repair damaged heart tissue and improved function after a heart attack, in a new animal study.

Recommended for you

Researchers investigate the potential of spider silk protein for engineering artificial heart

August 18, 2017
Ever more people are suffering from cardiac insufficiency, despite significant advances in preventing and minimising damage to the heart. The main cause of reduced cardiac functionality lies in the irreversible loss of cardiac ...

Lasers used to detect risk of heart attack and stroke

August 18, 2017
Patients at risk of heart attacks and strokes may be spotted earlier thanks to a diagnosis tool that uses near-infrared light to identify high-risk arterial plaques, according to research carried out at WMG, University of ...

How Gata4 helps mend a broken heart

August 15, 2017
During a heart attack, blood stops flowing into the heart; starved for oxygen, part of the heart muscle dies. The heart muscle does not regenerate; instead it replaces dead tissue with scars made of cells called fibroblasts ...

Injectable tissue patch could help repair damaged organs

August 14, 2017
A team of U of T Engineering researchers is mending broken hearts with an expanding tissue bandage a little smaller than a postage stamp.

'Fat but fit' are at increased risk of heart disease

August 14, 2017
Carrying extra weight could raise your risk of heart attack by more than a quarter, even if you are otherwise healthy.

Air pollution linked to cardiovascular disease; air purifiers may lessen impact

August 14, 2017
Exposure to high levels of air pollution increased stress hormone levels and negative metabolic changes in otherwise healthy, young adults in a recent study conducted in China. Air purifiers appeared to lessen the negative ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.